• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Lung Transplantation - Pipeline Review, H2 2012 Product Image

Lung Transplantation - Pipeline Review, H2 2012

  • ID: 2216771
  • July 2012
  • 43 pages
  • Global Markets Direct

Lung Transplantation – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Lung Transplantation - Pipeline Review, H2 2012', provides an overview of the Lung Transplantation therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. 'Lung Transplantation - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Transplantation.
- A review of the Lung Transplantation products under development by companies and READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Lung Transplantation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Lung Transplantation 7
Lung Transplantation Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Lung Transplantation Therapeutics – Products under Development by Companies 14
Companies Involved in Lung Transplantation Therapeutics Development 15
Quark Pharmaceuticals, Inc. 15
Vectura Group plc 16
PARI Pharma GmbH 17
APT Pharmaceuticals, Inc. 18
Fresenius Biotech GmbH 19
ImmuneWorks, LLC 20
Lung Transplantation – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Pulminiq - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Respiratory And Inflammatory Diseases Program - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
IW001 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ATG-Fresenius S - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
L-CsA - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
VR909 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Lung Transplantation Therapeutics – Drug Profile Updates 36
Lung Transplantation Therapeutics - Dormant Products 37
Lung Transplantation – Product Development Milestones 38
Featured News & Press Releases 38
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 38
May 16, 2011: Chugai Pharma Files Application Seeking Japanese Approval For Pediatric Dosage And Administration Of CellCept 39
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA 39
Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 40
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products Under Development for Lung Transplantation, H2 2012 7
Products under Development for Lung Transplantation – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Quark Pharmaceuticals, Inc., H2 2012 15
Vectura Group plc, H2 2012 16
PARI Pharma GmbH, H2 2012 17
APT Pharmaceuticals, Inc., H2 2012 18
Fresenius Biotech GmbH, H2 2012 19
ImmuneWorks, LLC, H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Lung Transplantation Therapeutics – Drug Profile Updates 36
Lung Transplantation Therapeutics – Dormant Products 37

List of Figures
Number of Products under Development for Lung Transplantation, H2 2012 7
Products under Development for Lung Transplantation – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos